GDC-0570 is a novel, potent, selective, orally active pan- PIM inhibitor. GDC-0570 demonstrates synergistic antitumor efficacy when combined with Sotorasib ( HY-114277 ) in acquired KRASis-resistant NSCLC.
Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Pim
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.